Superficial Punctate Keratitis Market Size 2032 Market Drivers & Barriers, Clinical Trials And Latest Drugs Approvals

(MENAFN- EIN Presswire)

Surgical Site Infections market Size

Superficial Punctate Keratitis Market

DELHI, DELHI, INDIA, June 19, 2024 /EINPresswire / -- DelveInsight's "Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Explore the intricate details of the Surgical Site Infections Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Surgical Site Infections Market Forecast. Click here to stay ahead in healthcare innovation @ Surgical Site Infections Market Size

Key Takeaways from Surgical Site Infections Market Research Report
. March 2024: Zurex Pharma Inc. announced a study of Phase 3 clinical trials for 70% v/v Isopropyl Alcohol Surgical Solution and 2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol. This study will evaluate a new topical skin antiseptic perioperative preparation and the standard of care to determine efficacy on the rates of surgical site infections of surgical patients. Safety will also be assessed.
. March 2024: Diakonie-Klinikum Schwäbisch Hall gGmbH- A Prospective, Controlled Monocentric Study Evaluating the 6:1 Suture Technique Using Suture Material Monomax® for Abdominal Wall Closure After Primary Abdominal Incision.
. March 2024: MB Pharma S.R.O. announced a study of Phase 1 & 2 clinical trials for IMP. The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing.
. March 2024: Karolinska University Hospital- This prospective randomized study aims to determine whether intermittent pneumatic compression (IPC), 75 patients, beneath functional bracing compared to treatment-as-usual in plaster cast, 75 patients, can reduce the Venous Thromboembolism (VTE) incidence and promote healing of sutured acute Achilles tendon ruptures.
. The increase in market size is a direct consequence of the increasing incident population of Surgical Site Infections patients in the 7MM.
. According to Centers for Disease Control and Prevention (n.d), SSIs are among the most common healthcare associated infections (HAI) (22% of all infections). 2%-5% of patients undergoing inpatient surgery develop aSSI. Each SSI is associated with approximately 7-10 additional postoperative hospital days.
. The leading Surgical Site Infections Companies working in the market include Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, Dr. Reddy's Laboratories Ltd., Zurex Pharma, and others.
. Promising Surgical Site Infections Pipeline Therapies in the various stages of development include Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others.

Navigate the complexities of the Surgical Site Infections Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Surgical Site Infections Market Forecast. Click here to get more insights @ Surgical Site Infections Treatment Market

Surgical Site Infections Epidemiology Segmentation in the 7MM
. Surgical Site Infections Incident Cases
. Surgical Site Infections Organ-specific Cases
. Surgical Site Infections Treatable Cases
. Surgical Site Infections Type-specific Cases

Delve deep into the Surgical Site Infections Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Surgical Site Infections Market Forecast. Click here to shape the future @ Surgical Site Infections Epidemiology Insights

Surgical Site Infections Market Landscape
People having surgery are cared for by healthcare providers that monitor surgical site infection rates (including post discharge infections) and provide feedback to relevant staff and stakeholders for continuous improvement through adjustment of clinical practice. As surgical site infections take a massive toll on resources and cause morbidity and mortality, there are many general rules and guidelines in place to prevent them in the first place. These include preoperative skin preparation, using films on the skin, theatre sterility rules, perioperative and postoperative prophylactic antibiotics, and dressings. Also, improving the patient's natural defense mechanisms such as early mobilization and improving nutritional status.

Surgical Site Infections Therapies and Companies
. Ciprodiazole: MinaPharm Pharmaceuticals
. DFA-02 Antibiotic Gel: Duke Clinical Research Institute
. ZuraPrep: Zurex Pharma, Inc.
. Ertapenem: Merck Sharp & Dohme LLC
. XF-73: Destiny Pharma Plc
. D-PLEX: PolyPid Ltd.
. cefuroxime: GlaxoSmithKline
. Dalbavancin: Durata Therapeutics
. daptomycin: Cubist Pharmaceutical
. ZuraGard: Zurex Pharma, Inc.

Unlock insights into the Surgical Site Infections Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Surgical Site Infections Market Forecast. Click here @ Surgical Site Infections Market Drivers and Barriers-

Surgical Site Infections Drugs Uptake
. Zurex Pharma, Inc. is evaluating ZuraGard, new topical skin antiseptic perioperative preparation and the standard of care to determine efficacy on the rates of surgical site infections of surgical patients. It is being developed as an applicator which rapidly saturates the sponge tip and reduce prep time. Its is patented hourglass design and thumb-guide activation enable onehand application. In clinical trials, ZuraGard showed less skin irritation, and overall greater microbial reduction compared to a common 2% w/v CHG/70%v/v Isopropyl Alcohol product. Presently it is in Phase III stage.
. PolyPid Ltd. Is conducting Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the standard of care (SoC), compared to a SoC treated control arm, in prevention of Post Abdominal Surgery Incisional Infection. D-PLEX is a new formulation of extended controlled release of Doxycycline in the applied area for about 30 days.

Surgical Site Infections Market Dynamics
Surgical Site Infections market dynamics are anticipated to change in the coming years due to the rising awareness of the disease and better approaches to therapy development worldwide. The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Surgical Site Infections market or expected to get launched during the study period. The analysis covers Surgical Site Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

Gain a strategic edge in the Surgical Site Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Surgical Site Infections Market Forecast. Click here to lead in advancements @ Surgical Site Infections Clinical Trials Assessment-

Scope of the Surgical Site Infections Market Report
. Coverage- 7MM
. Study Period- 2019-2032
. Surgical Site Infections Companies- Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, Dr. Reddy's Laboratories Ltd., Zurex Pharma, and others.
. Surgical Site Infections Pipeline Therapies- Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others.
. Surgical Site Infections Market Dynamics: Surgical Site Infections Market Drivers and Barriers

Discover the latest advancements in Surgical Site Infections Treatment by visiting our website. Stay informed about how we're transforming the future @

Table of Content
1. Key Insights
2. Executive Summary of Surgical Site Infections (SSI)
3. Competitive Intelligence Analysis for Surgical Site Infections (SSI)
4. Surgical Site Infections (SSI): Market Overview at a Glance
5. Surgical Site Infections (SSI): Disease Background and Overview
6. Patient Journey
7. Surgical Site Infections (SSI) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Surgical Site Infections (SSI) Unmet Needs
10. Key Endpoints of Surgical Site Infections (SSI) Treatment
11. Surgical Site Infections (SSI) Marketed Products
12. Surgical Site Infections (SSI) Emerging Therapies
13. Surgical Site Infections (SSI): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Surgical Site Infections (SSI)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

MENAFN19062024003118003196ID1108348263